X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4130) 4130
Publication (298) 298
Book Review (108) 108
Book Chapter (49) 49
Dissertation (6) 6
Conference Proceeding (5) 5
Data Set (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2347) 2347
index medicus (2202) 2202
infliximab (1418) 1418
female (1335) 1335
anti-tnf (1300) 1300
male (1282) 1282
tumor necrosis factor-alpha - antagonists & inhibitors (1251) 1251
rheumatology (1161) 1161
rheumatoid arthritis (1063) 1063
middle aged (1024) 1024
adult (1011) 1011
adalimumab (876) 876
anti-tnf therapy (788) 788
treatment outcome (772) 772
rheumatoid-arthritis (734) 734
etanercept (723) 723
antirheumatic agents - therapeutic use (711) 711
arthritis, rheumatoid - drug therapy (698) 698
gastroenterology & hepatology (630) 630
antibodies, monoclonal - therapeutic use (614) 614
therapy (574) 574
crohn's disease (559) 559
aged (543) 543
crohns-disease (512) 512
inflammatory bowel disease (479) 479
inflammatory-bowel-disease (477) 477
anti-tnf-alpha (451) 451
double-blind (447) 447
arthritis (436) 436
care and treatment (411) 411
immunology (388) 388
pharmacology & pharmacy (385) 385
efficacy (381) 381
tumor necrosis factor (379) 379
tumor-necrosis-factor (366) 366
ulcerative colitis (363) 363
ankylosing spondylitis (354) 354
methotrexate (354) 354
medicine & public health (341) 341
necrosis-factor-alpha (332) 332
safety (332) 332
risk factors (331) 331
tumor necrosis factor-tnf (329) 329
psoriasis (312) 312
retrospective studies (300) 300
young adult (297) 297
antirheumatic agents - adverse effects (296) 296
severity of illness index (295) 295
crohn disease - drug therapy (294) 294
drug therapy (292) 292
animals (291) 291
rheumatoid factor (272) 272
immunosuppressive agents - therapeutic use (267) 267
antibodies, monoclonal - adverse effects (263) 263
patients (259) 259
disease (258) 258
inflammation (258) 258
adolescent (255) 255
treatment (250) 250
analysis (249) 249
risk (240) 240
anti-tnf-α (239) 239
placebo-controlled trial (237) 237
tuberculosis (233) 233
tumor necrosis factor-alpha - immunology (232) 232
health aspects (230) 230
inflammatory bowel diseases - drug therapy (229) 229
antibodies, monoclonal, humanized - therapeutic use (227) 227
medicine, general & internal (224) 224
receptors, tumor necrosis factor - therapeutic use (224) 224
immunoglobulin g - therapeutic use (223) 223
ulcerative-colitis (217) 217
anti-inflammatory agents - therapeutic use (216) 216
anti-tnf agents (213) 213
spondylitis, ankylosing - drug therapy (209) 209
monoclonal antibodies (208) 208
psoriatic arthritis (204) 204
biologics (203) 203
ankylosing-spondylitis (202) 202
abridged index medicus (201) 201
follow-up studies (201) 201
monoclonal-antibody (200) 200
internal medicine (199) 199
time factors (193) 193
remission (191) 191
anti-tnfα (188) 188
infliximab - therapeutic use (188) 188
certolizumab pegol (186) 186
prospective studies (186) 186
arthritis, rheumatoid - immunology (183) 183
drug therapy, combination (183) 183
management (179) 179
maintenance therapy (175) 175
cytokines (174) 174
research (174) 174
anti-tnf alpha (173) 173
adalimumab - therapeutic use (171) 171
dermatology (167) 167
biological products - therapeutic use (161) 161
tumors (161) 161
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3828) 3828
French (157) 157
Spanish (73) 73
German (40) 40
Korean (21) 21
Japanese (19) 19
Portuguese (14) 14
Polish (13) 13
Turkish (5) 5
Czech (4) 4
Hungarian (3) 3
Russian (3) 3
Slovak (2) 2
Slovenian (2) 2
Arabic (1) 1
Chinese (1) 1
Estonian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2017, Volume 76, Issue 7, pp. 1253 - 1262
ObjectivesTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib... 
Cardiovascular Disease | Infections | Treatment | Tuberculosis | Rheumatoid Arthritis | JAK INHIBITOR | MODIFYING ANTIRHEUMATIC DRUGS | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | HERPES-ZOSTER | ANTI-TNF THERAPY | GASTROINTESTINAL PERFORATIONS | OPPORTUNISTIC INFECTIONS | RHEUMATOLOGY | NECROSIS FACTOR THERAPY | SERIOUS INFECTIONS | Tuberculosis - epidemiology | Herpes Zoster - etiology | Neoplasms - etiology | Humans | Middle Aged | Tuberculosis - etiology | Male | Protein Kinase Inhibitors - adverse effects | Infection - etiology | Incidence | Opportunistic Infections - etiology | Young Adult | Infection - epidemiology | Time Factors | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Opportunistic Infections - immunology | Herpes Zoster - epidemiology | Herpes Zoster - immunology | Opportunistic Infections - epidemiology | Infection - immunology | Clinical Trials as Topic | Tuberculosis - immunology | Neoplasms - immunology | Piperidines - adverse effects | Adolescent | Pyrimidines - adverse effects | Aged | Immunocompromised Host | Neoplasms - epidemiology | Clinical trials | Care and treatment | Research | Tofacitinib | Rheumatoid arthritis | Analysis | Herpes zoster | Melanoma | Data processing | Cancer therapies | Inflammatory diseases | Data bases | Skin cancer | Studies | Algorithms | Surveillance | Data collection | Janus kinase | Chronic obstructive pulmonary disease | Health risk assessment | Clinical and Epidemiological Research | 1506
Journal Article
Journal Article
Journal Article
Journal Article
Clinics in Chest Medicine, ISSN 0272-5231, 12/2015, Volume 36, Issue 4, pp. 751 - 767
Journal Article
Contemporary Nurse, ISSN 1037-6178, 01/2018, Volume 54, Issue 1, pp. 108 - 119
Background: Anti-tumor necrosis factor-α (anti-TNF-α) drugs used in the treatment of rheumatologic diseases. Objective: This study was conducted to examine the... 
nursing | adherence | telephone counseling | anti-TNF-α treatment | RHEUMATOID-ARTHRITIS | CROHNS-DISEASE | SAFETY | anti-TNF-alpha treatment | FOLLOW-UP | CARE | DRUG SURVIVAL | THERAPY | INFLIXIMAB | MEDICATION ADHERENCE | PSORIASIS
Journal Article
Arthritis and Rheumatology, ISSN 2326-5191, 09/2018, Volume 70, Issue 9, pp. 1500 - 1507
Objective. Since Behcet's syndrome (BS) is the prototype of inflammation-induced thrombosis, immunosuppressants are recommended in place of anticoagulants. We... 
MULTICENTER | MANAGEMENT | RHEUMATOLOGY | ANTI-TNF-ALPHA
Journal Article